Breaking News
Get 55% Off 0
Selloff or Market Correction? Either Way, Here's What to Do Next
See Overvalued Stocks
Close

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (BTEC)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
6.31 +0.11    +1.77%
20/12 - Closed. Currency in USD
Type:  ETF
Market:  United Kingdom
ISIN:  IE00BYXG2H39 
SEDOL:  BYXG2H3
Asset Class:  Equity
  • Volume: 144,272
  • Bid/Ask: 6.18 / 6.45
  • Day's Range: 6.18 - 6.29
iShares Nasdaq US Biotechnology UCITS USD (Acc) 6.31 +0.11 +1.77%

BTEC Recent Sentiments

 
Information on users’ sentiments for the iShares Nasdaq US Biotechnology UCITS USD (Acc) ETF, which are displayed both on charts of different periods of time and on a detailed table.
Start Date Username Call Open Rate End Date Chg. %
Jun 29, 2024 Pompeyo Curbelo   6.58 Jul 01, 2024 @ 6.61 +0.46%
Sep 22, 2022 Giuliano Giudici   5.36 Oct 14, 2022 @ 5.59 +4.29%
Jan 12, 2022 Tomasz Grzelczyk   6.45 Feb 04, 2022 @ 5.84 -9.46%
Sep 29, 2021 Jaroslaw Szewczyk   7.31 Oct 22, 2021 @ 7.00 -4.24%
Sep 13, 2021 Sot Fol   7.60 Oct 08, 2021 @ 6.99 -8.03%
Jul 14, 2021 Tomasz Grzelczyk   7.20 Aug 06, 2021 @ 7.60 +5.56%
Jun 22, 2021 Nuno Branco   7.18 Jul 16, 2021 @ 7.20 +0.28%
May 10, 2021 Tomasz Grzelczyk   6.74 Jun 04, 2021 @ 6.90 -2.37%
Apr 01, 2021 Michael Lyons   6.80 Apr 23, 2021 @ 6.96 -2.35%
Feb 08, 2021 Luis Alfredo   7.63 Mar 05, 2021 @ 6.42 -15.86%
Feb 02, 2021 Javier Suay Antón   7.37 Feb 26, 2021 @ 7.01 -4.88%
Feb 01, 2021 Paco Valor   7.28 Feb 26, 2021 @ 7.01 -3.71%
Jan 25, 2021 Patricio Flores...   7.51 Feb 19, 2021 @ 7.52 +0.13%
Jan 15, 2021 Leonkia   7.25 Feb 05, 2021 @ 7.52 +3.72%
Dec 29, 2020 Nastia Simaityte   6.93 Dec 29, 2020 @ 6.93 0.00%
Sep 28, 2020 Stelios Piperidis   6.05 Oct 23, 2020 @ 6.11 +0.99%
Aug 07, 2020 test test   6.11 Aug 28, 2020 @ 5.95 -2.62%
May 21, 2020 Lambros Katsonis   5.97 Jun 12, 2020 @ 5.71 -4.36%
Apr 22, 2020 CJ Refalo   5.59 May 15, 2020 @ 5.85 +4.65%
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BTEC Comments

Write your thoughts about iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email